Tango Soars 840% as Fund Buys $164M; DeepValue Warns of Overvaluation

What happened

Tango Therapeutics shares have surged 840% following a disclosure that a fund purchased an additional $164 million of the stock, reflecting intense investor enthusiasm for its PRMT5 inhibitor vopimetostat in MTAP-deleted cancers. However, the DeepValue Master Report maintains a 'POTENTIAL SELL' rating, warning that the stock at $12.51 already prices in substantial success despite the company remaining pre-revenue and pre-pivotal. The report highlights that Tango's balance sheet provides runway into 2028 but no intrinsic earnings support, and the termination of its Gilead collaboration revenue leaves it entirely dependent on clinical execution and equity markets. Vopimetostat's Phase 1/2 data, while encouraging, lack randomized comparison, and any competitive or regulatory setback could trigger a severe re-rating. The fund's massive buy provides temporary sentiment support, but the underlying risk/reward skews heavily to the downside given the stock's 350% twelve-month run.

Implication

While the fund's buying may create short-term momentum, it does not alter the fundamental overvaluation: Tango trades at 8.7x book with negative earnings and cash flow, and the bear case implies 44% downside from current levels. The bull case offers only limited upside for a low-probability outcome, making the risk/reward unattractive. The thesis remains dependent on flawless execution of vopimetostat's pivotal trial starting in 2026, with no room for error in a competitive field including Amgen. Investors should consider trimming into strength and only adding on a material pullback below the recent $8.66 financing level.

Thesis delta

The fund's disclosed purchase injects institutional conviction but does not change the core overvaluation thesis; the stock's 840% surge already prices in substantial vopimetostat success. The deep value analysis sees this as amplifying rather than altering the risk, with the company still pre-commercial and the stock trading at a level that embeds high success probability not yet de-risked by pivotal data.